- Home
- LZ vs VERA Comparison
LZ vs VERA Comparison
Compare LZ & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LZ | VERA |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 2.8B |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LZ | VERA |
|---|---|---|
| Price | $6.28 | $41.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $9.79 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 2.8M | 967.1K |
| Earning Date | 05-19-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $756,043,000.00 | N/A |
| Revenue This Year | $11.50 | N/A |
| Revenue Next Year | $7.11 | $445.28 |
| P/E Ratio | $78.50 | ★ N/A |
| Revenue Growth | ★ 10.88 | N/A |
| 52 Week Low | $6.14 | $18.53 |
| 52 Week High | $12.40 | $56.05 |
Technical Indicators
Market Signals| Indicator | LZ | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 32.83 | 50.83 |
| Support Level | N/A | $40.87 |
| Resistance Level | $7.23 | $56.05 |
| Average True Range (ATR) | 0.36 | 2.09 |
| MACD | 0.04 | 0.13 |
| Stochastic Oscillator | 10.33 | 69.26 |
Price Performance
Historical ComparisonAbout LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.